FDA pharmacologic class
Protease Inhibitor
5 medicines are in FDA's class of protease inhibitors: darunavir (Prezista), atazanavir (Reyataz), ritonavir (Norvir), fosamprenavir and nelfinavir (Viracept); 4 combination products also contain one. 5 of the 9 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is ritonavir 100 mg tablet at $0.607 per tablet (NADAC).
Which medicines are protease inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Darunavir | Prezista | 13 labelers | $1.16 per tablet 600 mg tablet | No | No current entry | 0 |
| Atazanavir | Reyataz | 4 labelers | $2.23 per capsule 300 mg capsule | No | No current entry | 0 |
| Ritonavir | Norvir | 7 labelers | $0.607 per tablet 100 mg tablet | Yes | A presentation being discontinued | 1 |
| Lopinavir and ritonavir | Kaletra | 3 labelers | $4.46 per tablet 200-50 mg tablet | No | A presentation being discontinued | 0 |
| Cobicistat and darunavir | Prezcobix | none listed | $79.99 per tablet 800 mg-150 mg tablet | No | No current entry | 0 |
| Fosamprenavir | none listed | 2 labelers | n/a | No | No current entry | 0 |
| Nelfinavir | Viracept | none listed | n/a | No | No current entry | 1 |
| Atazanavir and cobicistat | Evotaz | none listed | $52.05 per tablet 300 mg-150 mg tablet | No | A presentation being discontinued | 0 |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Symtuza | none listed | $152.87 per tablet 800-150-200-10 mg tablet | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price